ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vaniprevir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2020-02-08

Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection.

Gao W, Webber AL, Maxwell J, Anderson M, Caro L, Chung C, Miltenburg AMM, Popa S, Van Dyck K, Wenning L, Mangin E, Fandozzi C, Railkar R, Shire NJ, Fraser I, Howell B, Talal AH, Stoch SA.

Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cpt.1737

Bibliografisk träff 2017-08-10

Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men.

Caro L, de Hoon J, Depré M, Cilissen C, Miller J, Gao W, Panebianco D, Guo Z, Troemel SL, Anderson MS, Uemura N, Butterton J, Wagner J, Wright DH.

Clin Transl Sci · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/cts.12482

Bibliografisk träff 2017-07-05

Phase Separation Macrocyclization in a Complex Pharmaceutical Setting: Application toward the Synthesis of Vaniprevir.

Godin É, Bédard AC, Raymond M, Collins SK.

J Org Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.joc.7b01308

Bibliografisk träff 2016-10-01

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.

Kumada H, Mochida S, Suzuki F, Chayama K, Karino Y, Nakamura K, Fujimoto G, Howe AY, Ludmerer SW, Mobashery N.

J Gastroenterol Hepatol · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1111/jgh.13328

Bibliografisk träff 2016-09-02

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA.

J Am Chem Soc · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jacs.6b06454

Bibliografisk träff 2016-03-03

HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.

Ludmerer SW, Hirano T, Black S, Howe AY, Chang W, Takase A, Nakamura K, Tanaka Y, Kumada H, Hayashi N, Nickle D.

Antiviral Res · clinical trial, phase iii; journal article · DOI 10.1016/j.antiviral.2016.03.004

Bibliografisk träff 2015-12-01

[Vaniprevir with pegylated interferon and ribavirin in treatment for chronic hepatitis C].

Takehara T.

Nihon Rinsho · journal article

Bibliografisk träff 2015-11-10

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.

Uchida T, Hiraga N, Imamura M, Yoshimi S, Kan H, Miyaki E, Tsuge M, Abe H, Hayes CN, Aikata H, Ishida Y, Tateno C, Ellis JD, Chayama K.

Virus Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.virusres.2015.11.010

Bibliografisk träff 2015-09-25

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.

Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A, Howe AY, Ludmerer SW, Mobashery N.

J Gastroenterol · clinical trial, phase iii; comparative study; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00535-015-1120-x

Bibliografisk träff 2015-09-01

[Preclinical and clinical properties of vaniprevir (VANIHEP® Capsules 150 mg), a novel therapeutic agent for hepatitis C].

Kinoshita K, Iwasa T, Takase A, Nakamura K.

Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.146.159

Bibliografisk träff 2015-04-07

Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.

Wright DH, Caro L, Cerra M, Panorchan P, Du L, Anderson M, Potthoff A, Nachbar RB, Wagner J, Manns MP, Talal AH.

Antivir Ther · clinical trial; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3851/imp2958

Bibliografisk träff 2014-08-13

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study.

Hayashi N, Mobashery N, Izumi N.

J Gastroenterol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00535-014-0979-2

Bibliografisk träff 2014-07-04

A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.

Takayama K, Furusyo N, Ogawa E, Shimizu M, Hiramine S, Mitsumoto F, Ura K, Toyoda K, Murata M, Hayashi J.

J Infect Chemother · journal article; case reports · DOI 10.1016/j.jiac.2014.06.002

Bibliografisk träff 2013-10-10

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.

Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, Bourque M, Bhanja S, Strizki J, Barnard RJ, Hwang PM, DiNubile MJ, Mobashery N.

Clin Gastroenterol Hepatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.cgh.2013.09.067

Bibliografisk träff 2013-06-28

Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.

Xue W, Ban Y, Liu H, Yao X.

J Chem Inf Model · research support, non-u.s. gov't; journal article · DOI 10.1021/ci400060j

Bibliografisk träff 2013-06-10

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.virol.2013.05.013

Bibliografisk träff 2013-06-07

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N.

Antiviral Res · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.antiviral.2013.05.015

Bibliografisk träff 2013-02-21

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment.

Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, Barnard RJ, An D, Gress J, Hwang P, Mobashery N.

J Hepatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jhep.2013.02.008

Bibliografisk träff 2012-07-26

The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA.

PLoS Pathog · research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.ppat.1002832

Bibliografisk träff 2012-07-17

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.

Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW, MK-7009 Protocol 007 Study Group.

Hepatology · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/hep.25743

Bibliografisk träff 2012-04-10

Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.

Kong J, Chen CY, Balsells-Padros J, Cao Y, Dunn RF, Dolman SJ, Janey J, Li H, Zacuto MJ.

J Org Chem · journal article · DOI 10.1021/jo3001595

Bibliografisk träff 2011-08-31

Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.

Song ZJ, Tellers DM, Journet M, Kuethe JT, Lieberman D, Humphrey G, Zhang F, Peng Z, Waters MS, Zewge D, Nolting A, Zhao D, Reamer RA, Dormer PG, Belyk KM, Davies IW, Devine PN, Tschaen DM.

J Org Chem · journal article · DOI 10.1021/jo2011494

Bibliografisk träff 2010-03-01

Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ.

J Med Chem · journal article · DOI 10.1021/jm9015526

Bibliografisk träff 2009-10-19

MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.

Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCauley JA, McIntyre CJ, Olsen DB, Rudd MT, Stahlhut M, Vacca JP.

Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.00677-09

Bibliografisk träff 2009-03-06

Effect of disease state on ionization during bioanalysis of MK-7009, a selective HCV NS3/NS4 protease inhibitor, in human plasma and human Tween-treated urine by high-performance liquid chromatography with tandem mass spectrometric detection.

Anderson MD, Breidinger SA, Woolf EJ.

J Chromatogr B Analyt Technol Biomed Life Sci · journal article · DOI 10.1016/j.jchromb.2009.02.069